IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
Paula Araya, Kohl T. Kinning, Christina Coughlan, Keith P. Smith, Ross E. Granrath, Belinda A Enriquez-Estrada, Kayleigh R Worek, Kelly D. Sullivan, Angela L. Rachubinski, Kristine Wolter‐Warmerdam, Francis Hickey, Matthew D. Galbraith, Huntington Potter, Joaquı́n M. Espinosa
Abstract
Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS.